Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Cash from Restructuring (2021 - 2022)

Historic Cash from Restructuring for Ernexa Therapeutics (ERNA) over the last 2 years, with Q4 2022 value amounting to -$5.8 million.

  • Ernexa Therapeutics' Cash from Restructuring changed N/A to -$5.8 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$5.8 million, marking a year-over-year change of. This contributed to the annual value of $5.8 million for FY2021, which is N/A changed from last year.
  • Latest data reveals that Ernexa Therapeutics reported Cash from Restructuring of -$5.8 million as of Q4 2022.
  • Ernexa Therapeutics' 5-year Cash from Restructuring high stood at $5.8 million for Q1 2021, and its period low was -$5.8 million during Q4 2022.